Get started
Work

Supplementary Figure 1 from A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies

Year: 2023
Type: supplementary-materials
Abstract: PDF file - 76KB, Dose proportionality. (A) --- Area under the curve for brentuximab vedotin; (B) --- Area under the curve for free MMAE
DOI: 10.1158/1078-0432.22447607
Authors: Michelle A. Fanale, Andres Forero-Torres, Joseph D. Rosenblatt, Ranjana H. Advani, Anna R. Franklin, Dana A. Kennedy, Tae H. Han, Eric L. Sievers, Nancy L. Bartlett
Language: English
Field: Medicine
Open Access status: gold
OpenAlex ID: W4362394401
Cites:
Cited by:
Related to: 10